

**INTERNAL INFORMATION ON FACTS AND CIRCUMSTANCES THAT TOOK
PLACE IN THE SECOND QUARTER OF 2016
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.**

- 1.1. There are no changes of the persons exercising control over the company.
- 1.2. There is no change in the Board of Directors; there are no changes in the representation, appointment or dismissal of a procurator.
- 1.3. There are no amendment and/or supplements in the Statute of the company in the second quarter of 2016.
- 1.4. Opening of procedure for liquidation and all material stages, connected with the procedure – no such procedure.
- 1.5. There are no insolvency proceedings against the company or its subsidiary and all material stages, connected with such proceedings.
- 1.6. Acquisition, lease or disposition of assets of big value under Art. 114, Para. 1, It. 1 of the Public Offering of Securities Act (POSA) – no such.
- 1.7. There is no decision on the conclusion, termination and rescission of a contract for joint venture.
- 1.8. Changes in the auditors of the Company – no changes
- 1.9. Announcement of the profit of the company - TCHAIKAPHARMA HIGH QUALITY MEDICINES INC. ended the second quarter of 2016 with a net profit of BGN 4 515 thousand /31.12.2015г. – BGN 7 780 thousand/.
- 1.10. There are no significant losses and reasons for them.
- 1.11. There are no unpredictable or unforeseen circumstances of extraordinary character, due to which the company or its subsidiary has suffered damages amounting to three or more percent of the company's equity.
- 1.12. The Company has not received and published a modified audit report.
- 1.13. Decision of the General Meeting on the type and amount of the dividend and the terms and conditions for its payment – there no decision for dividend distribution at the General Meeting held on 23.06.2016.
- 1.14. Receivables arising that are material to the company and their maturity – no.
- 1.15. There are no liquidity problems and measures for financial support.
- 1.16. Increase or decrease of the share capital – at the General Meeting held on 23.06.2016 it was decided to increase the share capital by BGN 7 000 thousand and increase the reserves by BGN 780 thousand.
- 1.17. No negotiations for acquisition of the company were held.
- 1.18. There are no essential contracts concluded or executed, which are not related to the core business of the company.
- 1.19. Opinion of the Governing Body in connection with a commercial offer – no such.
- 1.20. Termination or substantial reduction of the relations with clients, who form at least 10 percent of the revenues of the company for the last three years – no.
- 1.21. Introduction of new products and solutions on the market.

In the first semester of 2016 Tchaikapharma continued to be one of the leading pharmaceutical companies in Bulgaria, which continues to add new products to its diverse portfolio, and in the process

of Marketing Authorisation are the following medicinal products:

Cisaxa 2 mg/ml solution for injection/infusion - neuromuscular blocking agent that is used during surgical and other procedures and in the intensive care units, used as a co-general anesthetic agent for relieving the skeletal muscles and for supporting tracheal intubation and mechanical ventilation.

Levor 5 mg/ml solution for infusion - for the treatment of pneumonia or complicated infections of skin and soft tissue.

Atorva 40 mg and Atorva 80 mg film-coated tablets - statin that regulates the levels of lipids (fats).

Ibodria 3 mg/3 ml solution for injection and Ibodria 6 mg/6 ml concentrate for solution for infusion - for the treatment of bone diseases, bisphosphonates.

In the second quarter of 2016 the company successfully completed the international stage for the third decentralized procedure for the medicinal product Tamayra capsules hard. The procedure was adopted by the reference country Bulgaria, and by all six countries concerned - the Czech Republic, Romania, Greece, Slovakia, Portugal, Austria. After completion of the national phase of the procedure for the above mentioned medicinal product Tchaikapharma received Marketing Authorisation for use in Bulgaria.

Besides being a high quality manufacturer of medicinal products registered in the EU, Tchaikapharma expects four new Marketing Authorisations for the medicinal products Nordipin, Pisizif SR, Cardifriend and Bisor for the territory of Kosovo.

In the second quarter of 2016 the company filed four new product for registration in Kosovo: Rossta, Co-Telsart, Pizona and Diab MR, which also expect Marketing Authorisations.

1.22. There were no large orders /amounting to over 10 percent of the average revenues of the company for the last three years/.

1.23. There were no developments and/or changes in the volume of orders and the use of production capacity.

1.24. There was no suspension of sales of a product, forming significant part of the company's revenues.

1.25. Suspension of use, withdrawal of authorisation to operate / license / were not received.

1.26. There was no initiation or termination of legal or arbitration proceedings related to liabilities or receivables of the Company or its subsidiary, with claims of at least 10 percent of the company's equity.

1.27. The projected results were not updated.

1.28. There was no award or change of rating made by order of the company.

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC. notifies all concerned parties that the Interim Financial Report of the Company as of the 30th of June 2016 is not certified by a registered auditor.

Biser Georgiev
Executive Director